Research programme: cyclin dependent kinase inhibitors - MerckAlternative Names: CCT251545; MSC2530818
Latest Information Update: 02 May 2016
At a glance
- Originator Merck KGaA
- Class Small molecules
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors; Wnt signalling pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer